These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33683692)

  • 1. Immunocytochemical Detection of ALK and ROS1 Rearrangements in Lung Cancer Cytological Samples.
    Frankel D; Kaspi E; Roll P
    Methods Mol Biol; 2021; 2279():157-164. PubMed ID: 33683692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
    J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection of ALK and ROS1 rearrangements by immunocytochemistry on cytological samples].
    Frankel D; Bourlard D; Garcia S; Robaglia-Schlupp A; Peker E; Groliere A; Kaspi E; Roll P
    Ann Pathol; 2019 Jun; 39(3):227-236. PubMed ID: 30709602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization.
    Luk PP; Selinger CI; Mahar A; Cooper WA
    Arch Pathol Lab Med; 2018 Aug; 142(8):922-928. PubMed ID: 29902067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.
    Bozzetti C; Nizzoli R; Tiseo M; Squadrilli A; Lagrasta C; Buti S; Gasparro D; Zanoni D; Majori M; De Filippo M; Mazzoni F; Maddau C; Naldi N; Sammarelli G; Frati C; Pinto C; Ardizzoni A
    Diagn Cytopathol; 2015 Nov; 43(11):941-6. PubMed ID: 26152804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
    Cao H; Zheng J; Zhao J; Guo XJ; Zhou JY; Ding W; Zhou JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):120-125. PubMed ID: 32062881
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison between Immunocytochemistry, FISH and NGS for
    Frankel D; Nanni I; Ouafik L; Camilla C; Pellegrino E; Beaufils N; Greillier L; Dutau H; Astoul P; Kaspi E; Roll P
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
    Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
    Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma.
    Tang Z; Zhang J; Lu X; Wang W; Chen H; Robinson MK; Cheng J; Tang G; Medeiros LJ
    Mod Pathol; 2018 Feb; 31(2):307-312. PubMed ID: 28914263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma.
    Xu Y; Chang H; Wu L; Zhang X; Zhang L; Zhang J; Li Y; Shen L; Zhu X; Zhou X; Bai Q
    Exp Mol Pathol; 2020 Dec; 117():104548. PubMed ID: 32979347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.
    Pisapia P; Lozano MD; Vigliar E; Bellevicine C; Pepe F; Malapelle U; Troncone G
    Cancer Cytopathol; 2017 Nov; 125(11):817-830. PubMed ID: 28743163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
    Clavé S; Rodon N; Pijuan L; Díaz O; Lorenzo M; Rocha P; Taus Á; Blanco R; Bosch-Barrera J; Reguart N; de la Torre N; Oliveras G; Espinet B; Bellosillo B; Puig X; Arriola E; Salido M
    Clin Lung Cancer; 2019 Jul; 20(4):e421-e429. PubMed ID: 30898567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
    Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB
    J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas.
    Augustin J; Gabignon C; Scriva A; Menu L; Calmel C; Scatton O; Paye F; Fléjou JF; Praz F; Cervera P; Wendum D
    Virchows Arch; 2020 Jul; 477(1):33-45. PubMed ID: 32447492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
    BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.
    Piton N; Ruminy P; Gravet C; Marchand V; Colasse É; Lamy A; Naoures Mear CL; Bibeau F; Marguet F; Guisier F; Salaün M; Thiberville L; Jardin F; Sabourin JC
    Lab Invest; 2018 Mar; 98(3):371-379. PubMed ID: 29251734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiplex fluorescence in situ hybridization testing for anaplastic lymphoma kinase and c-ros oncogene 1 gene rearrangements on cytology smears in lung adenocarcinomas: comparative study with formalin-fixed paraffin-embedded sections.
    Nambirajan A; Rana D; Samant K; Prabakaran A; Malik P; Jain D
    J Am Soc Cytopathol; 2022; 11(3):154-164. PubMed ID: 35148960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotyping and cytomorphological subtyping of lung adenocarcinoma based on liquid-based cytology.
    Tanaka R; Sakamoto N; Suzuki H; Tachibana K; Ohtsuka K; Kishimoto K; Fujiwara M; Kamma H; Shibahara J; Kondo H
    Diagn Cytopathol; 2019 Jun; 47(6):564-570. PubMed ID: 30741488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.